mRNA Vaccines

1. Front Matter

   Pages i-xi

   PDF

2. mRNA-Based Vaccines and Mode of Action

   • Janina Gergen, Benjamin Petsch

   Pages 1-30

3. Self-amplifying mRNA-Based Vaccine Technology and Its Mode of Action

   • Giulietta Maruggi, Jeffrey B. Ulmer, Rino Rappuoli, Dong Yu

   Pages 31-70

4. Formulation and Delivery Technologies for mRNA Vaccines

   • Chunxi Zeng, Chengxiang Zhang, Patrick G. Walker, Yizhou Dong

   Pages 71-110

5. Messenger RNA-Based Vaccines Against Infectious Diseases

   • Mohamad-Gabriel Alameh, Drew Weissman, Norbert Pardi

   Pages 111-145

6. Advances in Development of mRNA-Based Therapeutics

   • Lei Huang, Luyao Zhang, Weiwei Li, Shiqiang Li, Jianguo Wen, Hangwen Li et al.

   Pages 147-166

7. Clinical Development of mRNA Vaccines: Challenges and Opportunities

   • Allison August, Luis Brito, Robert Paris, Tal Zaks

   Pages 167-186

8. Regulatory Considerations on the Development of mRNA Vaccines

   • Ramachandra Naik, Keith Peden

   Pages 187-205

The formulation and the technological advancements in RNA biology, chemistry, stability, and encapsulated delivery systems that have enabled the development of fully synthetic mRNA vaccines are discussed in this volume. The applications of the mRNA technology is covered, focusing on infectious diseases but also touching on other indications, such as immunotherapies and molecular therapies. Potent and long-lasting immune responses observed in animal models, encouraging data from early human clinical studies, together with the success of two mRNA-based COVID-19 vaccines support the use of mRNA-based vaccination as an attractive alternative to conventional vaccine approaches. Consequently, the development progress of the technology, particularly on production, capabilities, and clinical development is reviewed. Topics on safety, regulatory issues, and possible challenges to the mRNA vaccination approach round off this book. Thanks to their high potency, the prospect for generic,low-cost manufacturing processes, and entirely synthetic nature, the future for mRNA vaccines is highly promising. Importantly, mRNA vaccines have the potential to minimize the time between pathogen identification and vaccine release with a huge impact on public health.

As the mRNA-based vaccination technology has been progressing rapidly, the book is intended to be an end-to-end review series, covering everything from basic RNA biology and preclinical studies to the manufacturing strategy, clinical development and regulatory approval. It provides established RNA researchers and developers with updates on the latest advancements in the field and allows for a quick but comprehensive overview of this transformative technology, its application, and future potential.

• mRNA
• self-amplifying mRNA
• SAM
• vaccines
• synthetic delivery
• infectious diseases
• immunotherapy

• Senior Vice President of Research, Dynavax Technologies, Emeryville, USA

  Dong Yu

• CureVac AG, Tübingen, Germany

  Benjamin Petsch

Dr. Dong Yu currently is Senior Vice President of Research at Dynavax Technologies.  Prior to joining Dynavax, Dr. Yu was the Head of Preclinical R&D US at GSK Vaccines. He received the PhD from University of Connecticut Health Center. He was a faculty member at Washington University in Saint Louis and the Head of Microbial Molecular Biology at Novartis Vaccines prior to joining GSK Vaccines in 2015.  Dr. Yu authored over 40 publications in various journals and books. His publications reflect his research interests in virology, infectious diseases, and vaccines.

Dr. Benjamin Petsch, Senior Director Prophylactic Vaccine Research at CureVac AG, Benjamin Petsch joined CureVac in 2010 as a scientist in the vaccines department developing mRNA based vaccines against infectious diseases and is heading the department since 2013. He received his university degree from Ludwig-Maximilians-University of Munich and performed his doctoral thesis at the Friedrich-Loeffler-Institut, Tübingen, where he continued as a postdoc and research group leader working on mRNA vaccination against Influenza and on intervention of Influenza replication using small molecules. Dr. Petsch has a 10+ years scientific experience on mRNA based prophylactic vaccines. 

Policies and ethics